



Technology Brief: Immunosense®

Company Overview: Omnia Biosystems®

Omnia Biosystems® is a biotech company focused on developing innovative diagnostic and therapeutic solutions for cancer. The company's mission is to improve patient outcomes through the discovery and development of novel technologies that can enhance cancer detection, treatment, and management.

Background: Immunosense®

Immunosense® is a technology developed by Omnia Biosystems® that specializes in the early stage discovery and evaluation of biomarkers associated with metabolic reprogramming and immune evasion in cancers of epithelial origin, particularly those of luminal origin. The company's research aims to identify and develop effective cancer treatments that can improve patient outcomes.

Specifics

Immunosense® uses in vitro models of early stage malignancy to identify biomarkers associated with metabolic reprogramming and immune evasion mechanisms in cancers of epithelial origin. The company then validates these biomarkers in clinical cohorts to determine their relevance and potential clinical utility.

One of the key areas of focus for Immunosense® is the identification of biomarkers linked to Epidermal growth factor receptor (EGFR) signaling in cancer. These biomarkers have shown promising results in improving diagnosis, prognosis, and treatment selection for patients with HER2 positive cancers.

Position for Partnerships

Omnia Biosystems® is actively seeking partnerships with academic and industry collaborators to further develop and validate its biomarkers and explore their potential clinical applications. The company's expertise in early stage discovery and evaluation of biomarkers, combined with its access to clinical cohorts, provides a unique opportunity for partners to advance their research and development efforts in the field of cancer therapeutics.